ZRANB2

Across TCGA pan-cancer cohorts, ZRANB2 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated ZRANB2 data layer compared with 28 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher ZRANB2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated ZRANB2 expression acts as an unfavorable survival marker, although some lineages such as COAD and LUAD show a favorable association.

HNSC, CCRCC, and COAD are the cancer types where ZRANB2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Tertile	II,III,IV	0.607	0.909	<.001	93	view →
CCRCC	DFS	Median	All	0.527	0.922	.003	28	view →
COAD	DFS	Median	III,IV	1.000	0.841	.041	24	view →
LUAD	DFS	Median	All	0.848	0.640	.001	22	view →
PDAC	DFS	Median	All	0.452	0.260	.013	15	view →
UCEC	OS	Quartile	II,III,IV	0.502	1.000	.037	4	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

ZRANB2–HNSC (DFS)

Open the HNSC breakdown →